MIcroglial Colony Stimulating Factor-1 Receptor (CSF1R) in Alzheimer's Disease

Summary

A phase 1 randomised, placebo-controlled, single-blind study to characterise the biomarker effects of the CSF-1 receptor antagonist JNJ-40346527 in participants with mild cognitive impairment. A maximum of 54 participants will be recruited to the two part study. The first part of the study will identify whether it is possible to identify biomarkers that may be used in future studies with JNJ-40346527 and part 2 will investigate a minimal efficacious JNJ-40346527 dose.

Timeline

Start

2021-04-07

Primary completion

2022-02-18

Completion

2022-02-18

Drugs

Indications